Alessandra Mangia
Hepatology — Casa Sollievo della Sofferenza, Italy
Alessandra Mangia
LeadR Profile
Hepatology
Subspecialties: Gastroenterology - Infectiology - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 1994 - 2026
Number : 399
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Direct-Acting Antivirals in Patients with Comorbidities for the Simplified Management of HCV Infection: An Expert Review with a Focus on Sofosbuvir-Velpatasvir. comorbidity, polypharmacy, pharmaceutical preparations, virology, sofosbuvir, therapeutics, antiviral agents, infections | Viruses | 2026 | 0 |
| Predictive Value of Sustained Virologic Response at Week 4 in Patients with Hepatitis C Virus Infection Treated with Sofosbuvir/Velpatasvir. sexually transmitted diseases, hepatitis c, virology, predictive value of tests, sustained virologic response, sofosbuvir, viruses, therapeutics, infections, hepatitis, virus diseases | Viruses | 2026 | 0 |
| Advances in portal hypertension management: Evolution of the Baveno guidelines. hypertension, hypertension, portal, ligation, therapeutics, gastrointestinal diseases | World J Gastroenterol | 2025 | 0 |
| Safety Choice Drivers of the Coming Treatment Options for Non-Cirrhotic Metabolic Steatohepatitis. diabetes mellitus, safety, fibrosis, pharmaceutical preparations, non-alcoholic fatty liver disease, liver, obesity, therapeutics | Liver Int | 2025 | 1 |
| Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease in a Cohort of Patients With Chronic Hepatitis B. liver diseases, diabetes mellitus, research design, fibrosis, digestive system diseases, hepatitis, chronic, liver, ferritins, prevalence, risk factors, therapeutics, hepatitis b, hepatitis b, chronic, hepatitis, diabetes mellitus, type 2, liver stiffness | Clin Gastroenterol Hepatol | 2025 | 2 |
Clinical Studies 20
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
3 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Phase 3 Randomized Double Blind Placebo Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non Cirrhotic Nonalcoholic Steatohepatitis (NASH) Metabolic Dysfunction Associated Steatohepatitis (MASH) and Fibrosis 2023-505141-48-00 — safety, fibrosis, non-alcoholic fatty liver disease, alcoholics | Phase 3 | Recruiting | 2024 |
| A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis NCT05627362 — bile, cholangitis, safety, pharmaceutical preparations, bile ducts, tablets, liver, cholangitis, sclerosing | Phase 2 | Active not recruiting | 2022 |
| Research Study on Whether Semaglutide Works in People With Non alcoholic Steatohepatitis (NASH) NCT04822181 — liver diseases, skin, non-alcoholic fatty liver disease, liver, alcoholics, research, fatty liver, fatty liver, alcoholic, semaglutide | Phase 3 | Active not recruiting | 2021 |
LeadR Networks
Main global connection map